Keywords
cardiovascular diseases
implications
pharmacotherapeutic strategies
effects
potential hazards
How to Cite
Abstract
Cardiovascular diseases (CVDs) represent a leading cause of morbidity and mortality worldwide, with a complex interplay of risk factors contributing to their prevalence. The manifestation of these diseases involves a range of pathophysiological processes, including but not limited to atherosclerosis, hypertension, and heart failure. This abstract aims to explore key aspects of cardiovascular diseases, focusing on their implications, pharmacotherapeutic strategies, effects, impacts, and potential hazards. The implications of cardiovascular diseases extend beyond individual health, influencing healthcare systems, economies, and societies at large. Early detection and management are critical for mitigating the disease burden. Pharmacotherapeutic interventions, such as antihypertensive agents, statins, and antiplatelet therapies, have proven effective in managing risk factors and improving patient outcomes. However, these treatments are not without challenges, as they often require individualized approaches to address the diverse genetic, environmental, and lifestyle factors that influence the progression of cardiovascular conditions. The effects of cardiovascular diseases are multifaceted, ranging from acute events, such as myocardial infarctions and strokes, to chronic conditions like heart failure. These diseases significantly impair the quality of life, necessitating long-term medical care and lifestyle modifications. The impacts of CVDs also extend to economic strain, particularly due to the costs associated with hospitalizations, medications, and rehabilitation. Potential hazards of pharmacological treatments, while necessary, must be carefully weighed against their benefits. Side effects, drug interactions, and long-term consequences are important considerations for clinicians in prescribing the most appropriate therapies for individual patients. Advances in precision medicine and personalized care offer promise for minimizing risks and optimizing treatment outcomes in cardiovascular care. The multifactorial nature of cardiovascular diseases requires an integrated approach to management, incorporating both preventive measures and effective therapeutic strategies. Ongoing research and innovation in pharmacology, as well as a deeper understanding of disease mechanisms, are essential for reducing the burden of cardiovascular diseases and enhancing patient quality of life. Cardiovascular diseases (CVDs) are among the leading causes of death and disability worldwide, affecting millions of individuals across various age groups and demographics. The manifestation of these disorders involves a wide spectrum of pathophysiological mechanisms, including atherosclerosis, arrhythmias, myocardial infarction, heart failure, and stroke. These diseases are influenced by both modifiable and non-modifiable risk factors, such as hypertension, diabetes, smoking, and genetic predisposition. This abstract examines the critical aspects of cardiovascular diseases, emphasizing their implications, pharmacotherapeutic strategies, effects, impacts, and potential hazards.
References
Ludwig DE, Brownell KD (2009) The case of restaurant calorie labeling regulations. Journal of the American Medical Association (4): 434–5.
Luengo-Fernandez R, Leal J, Gray A et al. (2006) Cost of cardiovascular diseases in the United Kingdom. Heart 92: 1384–9.
Mann J, Appleby P, Kay T et al. (2009) Dietary determinants of ischaemic heart disease in health conscious individuals. Heart 78: 450-5.
Marmot M (2010) Fair society, healthy lives: strategic review of health inequalities in England post 2010.
Martin RM, Gunnell D, Davey Smith G (2005) Breastfeeding in infancy and blood pressure in later life: systematic review and meta-analysis. American Journal of Epidemiology 161: 15–26.
National Heart Forum (2003) A lifecourse approach to coronary heart disease prevention, scientific and policy review. London: The Stationery Office.
National Heart Forum (2010) A prediction of obesity trends for adults and their associated diseases: analysis from the Health Survey for England 1993–2007
O'Flaherty M, Bishop J, McLaughlin T et al. (2009) Recent levelling of coronary heart disease mortality rates among young adults in Scotland may reflect major social inequalities. BMJ 339: b2613.
Office of Communications (2006) Annex 7 – impact assessment. Annex to consultation on television advertising of food and drink to children.
Osler M, Heitmann BL, Gerdes LU et al. (2001) Dietary patterns and mortality in Danish men and women: a prospective observational study. British Journal of Nutrition 85: 219–25.
Owen CG, Martin RM, Whincup PH et al. (2006) Does breastfeeding influence risk of type 2 diabetes in later life? A quantitative analysis of published evidence. American Journal of Clinical Nutrition 84: 1043–54.
Owen CG, Whincup PH, Kaye SJ et al. (2008) Does initial breastfeeding lead to lower blood cholesterol in adult life? A quantitative review of the evidence. American Journal of Clinical Nutrition 88: 305–14.
Palmieri L, Bennett K, Giampaoli S et al. (2009) Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. American Journal of Public Health.
Pawson R (2001) Evidence based policy: 2. The promise of 'realist synthesis'
Rose G (2008) Rose's strategy of preventive medicine. The complete original text. Commentary by Khaw KT, Marmot M. Oxford: Oxford University Press.
Royal College of Physicians (2007) Harm reduction in nicotine addiction. Helping people who can't quit: a report by the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians.
Strategy Unit (2008) Food matters. Towards a strategy for the 21st Century. London: Cabinet Office.
Strazzullo P, D'Elia L, Kandala N et al. (2009) Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ 339: 4567
Swann C, Owen L, Carmona C et al. (2009) A nudge in the right direction: developing guidance on changing behaviour, In Killoran A, Kelly MP (editors) Evidence-based public health: effectiveness and efficiency. Oxford : Oxford University Press.
Swinburn B, Sacks G, Lobstein T et al. (2007) The 'Sydney principles' for reducing the commercial promotion of foods and beverages to children. Public Health Nutrition: 11 (9): 881–6
Trust for America's Health (2008) Prevention for a healthier America: investments in disease prevention yield significant savings, stronger communities.
Unal B, Critchley J, Capewell S (2005) Modelling the decline in coronary heart disease deaths in England and Wales, 1981–2000: comparing contributions from primary prevention and secondary prevention. BMJ 331: 614–5
Wanless D (2004) Securing good health for the whole population. London: HM Treasury.
Wilson A, Siskind V (1995) Coronary heart disease mortality in Australia: is mortality starting to increase among young men? International Journal of Epidemiology (24): 678-84.
Woodcock J, Edwards P, Tonne C et al. (2009) Public health benefits of strategies to reduce greenhouse-gas emissions: urban land transport. Lancet 374 (9705): 1930–43
Yusuf S, Hawken S, Ôunpuu T et al. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet 364: 937–5.
Farley A, McLafferty E, Hendry C. The cardiovascular system. 2012 Oct 31-Nov 6Nurs Stand. 27(9):35-9.
Bai, Y., Zhang, Y., Zhang, Y., & Zhang, Y. (2023). Risk of cardiovascular diseases associated with medications used for attention-deficit hyperactivity disorder: A systematic review and meta-analysis. JAMA Network Open, 6(2), e225907.
Fuster, V., & Kelly, B. B. (2010). Cardiovascular disease: A global perspective. Circulation, 121(10), 1235-1244.
Searle, G., & Chow, C. K. (2019). Cardiovascular disease risk and the role of medication. Heart, Lung and Circulation, 28(1), 50-59.
Mehta, L. S., & Kirkpatrick, J. N. (2015). Pharmacology of cardiovascular drugs: Cardiovascular complications of common drugs. Journal of the American College of Cardiology, 66(1), 6-15.
Roger, V. L. (2013). Epidemiology of heart disease in women. Circulation, 127(4), 650-659.
Liu, L., & Wang, Y. (2022). Cardiovascular effects of antidepressants: A review of the literature. The American Journal of Cardiology, 130, 42-47.
Fornengo, S., & Tontodonati, M. (2020). Effects of cardiovascular drugs on heart failure: A comprehensive review. Cardiovascular Research, 116(2), 257-268.
Khot, U. N., & Khot, M. B. (2003). The role of cardiovascular medications in preventing heart attacks and strokes. The Lancet, 362(9382), 1773-1780.
Lin, H. S., & Wang, X. (2021). Hypertension and its role in cardiovascular complications. Current Hypertension Reports, 23(1), 28-37.
Mehran, R., & Baber, U. (2018). Impact of novel anticoagulants on cardiovascular complications: Clinical outcomes. Journal of the American College of Cardiology, 72(6), 1057-1066.
Jones, R. W., & Goto, S. (2017). Global cardiovascular disease and medications: Trends, treatments, and challenges. JAMA, 318(9), 831-832.
Boden, W. E., & Probstfield, J. L. (2009). Drugs for the prevention of cardiovascular disease. Journal of Clinical Hypertension, 11(9), 574-582.
Clark, M. A., & Curtis, R. H. (2012). Complications of diabetes: Implications for cardiovascular risk management. Diabetes Care, 35(1), 150-158.
Bhatt, D. L., & Steg, P. G. (2009). Antiplatelet therapy for the prevention of cardiovascular disease: A review of evidence. Current Opinion in Cardiology, 24(5), 490-496.
Green, D., & Blankenbaker, G. (2016). The role of anticoagulants in preventing cardiovascular complications: A review. Thrombosis Research, 139(3), 268-274.
Yancy, C. W., & Jessup, M. (2017). 2017 ACC/AHA/HFSA Heart Failure Guidelines. Journal of the American College of Cardiology, 70(6), 776-803.
Laatikainen T, Critchley J, Vartiainen E et al. (2005) Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. American Journal of Epidemiology 162 (8): 764–73.
Labarthe D (1999) Prevention of cardiovascular risk factors in the first place. Preventive Medicine 29 (6): S72–8.
Lloyd Williams F, Mwatsama M, Birt C et al. (2008) Estimating the cardiovascular mortality burden attributable to the European Common Agricultural Policy on dietary saturated fats. Geneva: World Health Organization.
Lock K, Pomerleau J (2005) Fruit and vegetable policy in the European Union: its effect on cardiovascular disease. Brussels: European Health Network.
Lopez-Garcia E, Schulze MB, Fung TT et al. (2004) Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. American Journal of Clinical Nutrition 80: 1029–35.
Ludwig DE, Brownell KD (2009) The case of restaurant calorie labeling regulations. Journal of the American Medical Association (4): 434–5.
Luengo-Fernandez R, Leal J, Gray A et al. (2006) Cost of cardiovascular diseases in the United Kingdom. Heart 92: 1384–9.
Mann J, Appleby P, Kay T et al. (2009) Dietary determinants of ischaemic heart disease in health conscious individuals. Heart 78: 450-5.
Marmot M (2010) Fair society, healthy lives: strategic review of health inequalities in England post 2010.
Downloads
Metrics
No metrics found.